-
Results of a paper presented at the recent Annual Clinical Meeting of the American College of Obstetricians and Gynecologists suggest that an investigational low-dose contraceptive patch appears to be as effective as a combined oral contraceptive (COC).1
-
If your practice includes care of pregnant women, be sure they are being tested for chlamydia and gonorrhea. Results of a new national analysis of laboratory tests of 1.3 million pregnant women indicate just 59% and 57% of pregnant women were tested at least once for chlamydia and gonorrhea, respectively.
-
Sign up for the free Aug. 29 webinar, "Risk Made Real: A Case-Based Approach to Addressing Risk in Contraception," sponsored by the Association of Reproductive Health Professionals (ARHP).
-
Good news: According to a new analysis of National Survey of Family Growth (NSFG) data, researchers report an increase in the number of sexually experienced teens using highly effective contraceptive methods such as the intrauterine device, implant, pill, patch, ring, or injectable contraceptive.1
-
Research presented at the latest Clinical Meeting of the American College of Obstetricians and Gynecologists indicates that women using an oral contraceptive (OC) with a 26/2 dosing regimen had less severe hormone withdrawal-associated symptoms than those using a 21/7 pill.
-
Check your clinic storeroom for stock of the Sandoz oral contraceptive Introvale. The Princeton, NJ-based company issued a voluntary recall in June 2012 for 10 lots of the generic oral contraceptive following a recent report of a packaging flaw.
-
Patients who received treatment for depression within a year were identified in a Japanese database of more than 323,000 patients. The investigators asked 2354 patients to complete a questionnaire on depression with a specific focus on patient-physician relationships.
-
In this issue: Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
-
Several studies have implicated endometriosis as a risk factor for the subsequent development of invasive epithelial ovarian cancer.
-
Results of primary studies on and meta-analyses of the effects of vitamin D therapy on fracture risk have failed to conclusively demonstrate benefit.
